Woodline Partners LP Makes New Investment in Maze Therapeutics, Inc. $MAZE

Key Points

• Woodline Partners LP has invested $10.23 million in Maze Therapeutics, acquiring approximately 929,102 shares, representing 2.12% of the company.
• Maze Therapeutics reported earnings of ($0.77) per share for the last quarter, beating analysts' expectations by $0.02.
• Analyst ratings for Maze Therapeutics show a consensus of "Buy" with a price target averaging $26.33, reflecting optimistic outlook in the market.

Woodline Partners LP acquired a new position in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 929,102 shares of the company's stock, valued at approximately $10,229,000. Woodline Partners LP owned 2.12% of Maze Therapeutics as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. New York State Common Retirement Fund acquired a new stake in Maze Therapeutics in the 1st quarter valued at about $25,000. Corebridge Financial Inc. acquired a new stake in Maze Therapeutics during the first quarter valued at approximately $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Maze Therapeutics during the first quarter valued at approximately $57,000. Deutsche Bank AG acquired a new stake in Maze Therapeutics during the first quarter valued at approximately $98,000. Finally, Nuveen LLC acquired a new stake in Maze Therapeutics during the first quarter valued at approximately $125,000.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Wedbush assumed coverage on shares of Maze Therapeutics in a research note on Tuesday, July 8th. They set an "outperform" rating and a $17.00 target price for the company. Guggenheim increased their target price on shares of Maze Therapeutics from $19.00 to $34.00 and gave the company a "buy" rating in a research note on Monday. HC Wainwright increased their target price on shares of Maze Therapeutics from $34.00 to $50.00 and gave the company a "buy" rating in a research note on Friday, September 12th. BTIG Research increased their target price on shares of Maze Therapeutics from $30.00 to $37.00 and gave the company a "buy" rating in a research note on Friday, September 12th. Finally, Wall Street Zen upgraded Maze Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. Two research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to MarketBeat, Maze Therapeutics has an average rating of "Buy" and a consensus target price of $32.67.

Maze Therapeutics Trading Up 2.7%

Shares of NASDAQ MAZE traded up $0.63 during trading hours on Wednesday, hitting $24.09. The stock had a trading volume of 69,885 shares, compared to its average volume of 262,250. The firm's 50-day moving average price is $15.67 and its two-hundred day moving average price is $12.43. Maze Therapeutics, Inc. has a 52 week low of $6.71 and a 52 week high of $25.50.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.79) by $0.02.

Insider Transactions at Maze Therapeutics

In other Maze Therapeutics news, Director Richard H. Scheller sold 20,744 shares of the company's stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $22.37, for a total transaction of $464,043.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Maze Therapeutics Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.